JP2019508044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508044A5 JP2019508044A5 JP2018546653A JP2018546653A JP2019508044A5 JP 2019508044 A5 JP2019508044 A5 JP 2019508044A5 JP 2018546653 A JP2018546653 A JP 2018546653A JP 2018546653 A JP2018546653 A JP 2018546653A JP 2019508044 A5 JP2019508044 A5 JP 2019508044A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- recombinant nucleic
- acid vector
- sequence
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310551P | 2016-03-18 | 2016-03-18 | |
| US62/310,551 | 2016-03-18 | ||
| US201662313596P | 2016-03-25 | 2016-03-25 | |
| US62/313,596 | 2016-03-25 | ||
| PCT/US2017/023117 WO2017161360A2 (en) | 2016-03-18 | 2017-03-20 | Multimodal vector for dendritic cell infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508044A JP2019508044A (ja) | 2019-03-28 |
| JP2019508044A5 true JP2019508044A5 (enExample) | 2020-04-16 |
Family
ID=59850551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546653A Pending JP2019508044A (ja) | 2016-03-18 | 2017-03-20 | 樹状細胞感染のための多モードベクター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210198689A1 (enExample) |
| EP (1) | EP3430148A4 (enExample) |
| JP (1) | JP2019508044A (enExample) |
| KR (1) | KR20180118198A (enExample) |
| CN (1) | CN109312364A (enExample) |
| AU (1) | AU2017233072B2 (enExample) |
| CA (1) | CA3016389A1 (enExample) |
| IL (1) | IL261812A (enExample) |
| MX (1) | MX2018011306A (enExample) |
| SG (1) | SG11201808058PA (enExample) |
| WO (1) | WO2017161360A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201414021D0 (en) | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| SG11201708604TA (en) | 2015-04-30 | 2017-11-29 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
| AU2016311444B2 (en) | 2015-08-25 | 2019-02-07 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| CA3027911A1 (en) | 2016-06-30 | 2018-01-04 | Nant Holdings Ip, Llc | Coordinated treatment regimen to treat a tumor |
| MY197324A (en) | 2016-08-29 | 2023-06-13 | Akamis Bio Ltd | Adenovirus armed with bispecific t cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| JP7394628B2 (ja) | 2017-06-01 | 2023-12-08 | アカミス バイオ リミテッド | 腫瘍溶解性ウイルスおよび方法 |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4409097B2 (ja) * | 1998-12-09 | 2010-02-03 | アメリカ合衆国 | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
| PT1385538E (pt) * | 2001-04-05 | 2013-05-07 | Univ Johns Hopkins | Vacinas quiméricas compreendendo o domínio luminal de lamp-1 ou lamp-2 |
| WO2003039592A2 (de) * | 2001-11-09 | 2003-05-15 | Medigene Aktiengesellschaft | Zelluläre impfstoffe mit adjuvanzien |
| WO2004061113A1 (en) * | 2003-01-07 | 2004-07-22 | The University Of Hong Kong | Adeno-associated virus mediated b7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers |
| US8562970B2 (en) * | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
| EP1874348A4 (en) * | 2005-04-14 | 2009-10-28 | Univ Queensland | IMMUNOREGULATORY COMPOSITIONS AND THEIR USE |
| BR112013006699A2 (pt) * | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| CA2847057C (en) * | 2011-08-31 | 2019-06-11 | St. Jude Children's Research Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
| CN102533859A (zh) * | 2012-01-12 | 2012-07-04 | 中国人民解放军第二军医大学 | 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用 |
| EP3587455A1 (en) * | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| HUE043042T2 (hu) * | 2013-11-01 | 2019-07-29 | Pfizer | Vektorok prosztatához kapcsolódó antigének expressziójára |
| CA2928199C (en) * | 2013-11-05 | 2025-06-17 | Bavarian Nordic A/S | POLYTHERAPY FOR CANCER TREATMENT USING A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR |
| NZ721908A (en) * | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
| WO2015112626A1 (en) * | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| AU2015259510B2 (en) * | 2014-05-13 | 2020-10-01 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
-
2017
- 2017-03-20 SG SG11201808058PA patent/SG11201808058PA/en unknown
- 2017-03-20 CN CN201780017523.9A patent/CN109312364A/zh active Pending
- 2017-03-20 EP EP17767693.9A patent/EP3430148A4/en not_active Withdrawn
- 2017-03-20 US US16/081,014 patent/US20210198689A1/en not_active Abandoned
- 2017-03-20 KR KR1020187028404A patent/KR20180118198A/ko not_active Ceased
- 2017-03-20 CA CA3016389A patent/CA3016389A1/en not_active Abandoned
- 2017-03-20 WO PCT/US2017/023117 patent/WO2017161360A2/en not_active Ceased
- 2017-03-20 AU AU2017233072A patent/AU2017233072B2/en not_active Ceased
- 2017-03-20 MX MX2018011306A patent/MX2018011306A/es unknown
- 2017-03-20 JP JP2018546653A patent/JP2019508044A/ja active Pending
-
2018
- 2018-09-16 IL IL261812A patent/IL261812A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| Cui et al. | Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer | |
| JP2019176869A5 (enExample) | ||
| ES3049406T3 (en) | Methods for profiling the t-cell-receptor repertoire | |
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| US20180000912A1 (en) | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity | |
| JP2018508567A5 (enExample) | ||
| JP2014523406A5 (enExample) | ||
| JP2019524773A (ja) | 樹状細胞のトランスフェクション及びその方法 | |
| JP2017538401A5 (enExample) | ||
| WO2017161360A4 (en) | Multimodal vector for dendritic cell infection | |
| JP2017525336A5 (enExample) | ||
| Lin et al. | Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles | |
| Goyal et al. | Advancing cancer immunotherapy: the potential of mRNA vaccines as a promising therapeutic approach | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| CN110859968A (zh) | 激活对肿瘤的系统免疫反应的基因生物药物 | |
| Xu et al. | Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma | |
| Shariati et al. | mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy | |
| Odegard et al. | Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy | |
| JP2023017853A (ja) | 新規な癌抗原及び方法 | |
| JP2015524788A5 (enExample) | ||
| Crowley et al. | Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH | |
| Bellone et al. | Advances in dendritic cell-based therapeutic vaccines for cervical cancer | |
| JP2015529629A5 (enExample) | ||
| JP2023522198A (ja) | 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 |